A Once-Daily Dose-Ranging Study of GSK189075 [remogliflozin etabonate] Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naive Subjects.
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Remogliflozin etabonate (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 12 May 2009 Additional locations identified as reported by ClinicalTrials.gov.
- 27 Oct 2008 Actual start date changed from Sep 2007 to Aug 2007 as reported by ClinicalTrials.gov.